Administration of Endocannabinoids Prevents a Referred Hyperalgesia Associated with Inflammation of the Urinary Bladder
@article{FarquharSmith2001AdministrationOE, title={Administration of Endocannabinoids Prevents a Referred Hyperalgesia Associated with Inflammation of the Urinary Bladder}, author={W. Paul Farquhar-Smith and Andrew S. C. Rice}, journal={Anesthesiology}, year={2001}, volume={94}, pages={507-513} }
Background Referred hyperalgesia to a somatopically appropriate superficial site is a cardinal symptom of visceral inflammatory pain and has been demonstrated after turpentine-induced urinary bladder inflammation in the rat. The authors examined the effect of the endocannabinoids anandamide and palmitoylethanolamide on the referred hyperalgesia associated with this model. Methods After measurement of baseline limb withdrawal latencies to a noxious heat stimulus, the bladders of 50 female Wistar…
100 Citations
Intrathecal cannabinoid-1 receptor agonist prevents referred hyperalgesia in acute acrolein-induced cystitis in rats.
- Medicine, BiologyAmerican journal of clinical and experimental urology
- 2015
It is suggested that pain arising from cystitis may be inhibited by activation of spinal CB1R but the acute local response of the bladder appeared to be unaffected by stimulation of spinalCB1R.
Effect of palmitoylethanolamide on inflammatory and neuropathic pain in rats
- Biology, MedicineKorean journal of anesthesiology
- 2017
It is revealed that PEA might be effective in relieving inflammatory and neuropathic pain, especially pain induced by mechanical hyperalgesia, but not cold allodynia.
Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy.
- Biology, MedicineProstaglandins, leukotrienes, and essential fatty acids
- 2002
A mechanistic discussion of the "framework" for analgesia will be followed by a description of studies examining the role of endocannabinoids in relieving pain; since the elucidation of these effects was undertaken using synthetic cannabinoids, reference will also be made to such studies, in the context of endOCannabinoids.
Local activation of cannabinoid CB1 receptors in the urinary bladder reduces the inflammation-induced sensitization of bladder afferents
- Biology, MedicineMolecular pain
- 2011
Results demonstrate that sensitization of bladder afferents induced by inflammation is partly suppressed by intravesical activation of cannabinoid receptors, an effect that appears to be mediated by CB1 receptors.
Involvement of cannabinoid receptors in inflammatory hypersensitivity to colonic distension in rats
- Biology, MedicineNeurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
- 2006
It is concluded that colonic inflammation enhances the antinociceptive action of CB1 and CB2 receptor agonists, and activates an endogenous, CB1 receptor mediated, antinOCiceptive pathway.
Potential Future Pharmacological Treatment of Bladder Dysfunction.
- Biology, MedicineBasic & clinical pharmacology & toxicology
- 2016
Evidence suggests that components of the endocannabinoid system are involved in regulation of bladder function, but the roles of these channels for normal function and in pathological states have not been established, and so far adverse effects (hyperthermia) have hampered development of antagonists.
The role of endocannabinoids and their receptors on the regulation of bladder function and detrusor overactivity
- Biology, Medicine
- 2015
In conclusion, cannabinoid receptors are involved in normal micturition at both peripheral and CNS sites, data supported by in vitro studies where CB1 reduced neuronal activity and where both cannabinoid receptors modulated bladder contractility.
Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB(1)/CB(2) receptors.
- Biology, ChemistryEuropean journal of pharmacology
- 2002
A Novel Alternative in the Treatment of Detrusor Overactivity? In Vivo Activity of O-1602, the Newly Synthesized Agonist of GPR55 and GPR18 Cannabinoid Receptors
- Biology, MedicineMolecules
- 2020
O-1602 can improve DO, and may serve as a promising novel substance for the pharmacotherapy of bladder diseases and the level of specific biomarkers was examined.
References
SHOWING 1-10 OF 43 REFERENCES
Inflammation of the rat urinary bladder is associated with a referred thermal hyperalgesia which is nerve growth factor dependent.
- Biology, MedicineBritish journal of anaesthesia
- 1999
Findings increase the knowledge of the nature of visceral and referred pain and further implicate NGF in the hyperalgesic response to inflammation of the urinary bladder.
The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain
- Biology, MedicinePain
- 1998
Spinal and supraspinal components of cannabinoid-induced antinociception.
- Biology, PsychologyThe Journal of pharmacology and experimental therapeutics
- 1991
The purpose of this study was to investigate whether cannabinoids produce antinociception spinal and supraspinal sites of action. The antinociceptive effect of delta 9-tetrahydrocannabinol (3 or 10…
Mechanisms of referred visceral pain: uterine inflammation in the adult virgin rat results in neurogenic plasma extravasation in the skin
- Biology, MedicinePain
- 1997
The role of nerve growth factor in a model of visceral inflammation
- Biology, MedicineNeuroscience
- 1997
Effects of extracorporeal shock-wave lithotripsy on referred hyperalgesia from renal/ureteral calculosis
- MedicinePain
- 1994
Control of pain initiation by endogenous cannabinoids
- Biology, ChemistryNature
- 1998
It is shown that anandamide attenuates the pain behaviour produced by chemical damage to cutaneous tissue by interacting with CB1-like cannabinoid receptors located outside the CNS, and that locally generated an andamide and PEA may mediate this effect.